Common misconceptions around MRD for MM prognosis

Common misconceptions around MRD for MM prognosis

VJHemOnc

1 year
74 Views
Share Report
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Measurable residual disease (MRD) is used as a prognostic indictor in a variety of hematological maliganancies, including multiple myeloma (MM). We asked Bruno Paiva, PhD, of the University of Navarra, Navarra, Spain, about common misconceptions amongst clinicians when it comes to using MRD as a prognostic marker for MM at the 23rd congress of the European Hematology Association (EHA) 2018, held in Stockholm, Sweden. Dr Paiva discusses why patients are often misclassified as MRD-negative, as well as why MRD status should be treated as a simple biomarker that is complemented by other information.
Up Next Autoplay